Insights

Innovative Oncology Pipeline Ability Pharmaceuticals has a robust portfolio of first-in-class cancer therapies, with ABTL0812 showing promising results across multiple cancer types and preparation for phase 2b trials in pancreatic cancer. This positions the company as a key innovator in the oncology sector, offering multiple opportunities for collaboration or licensing deals with pharmaceutical firms seeking cutting-edge treatments.

Strong Clinical Progress Recent successful phase 2a trial outcomes and ongoing international clinical trials demonstrate the company’s capability to advance promising therapies. This positive clinical track record can encourage potential partners and healthcare providers to consider early adoption and support for ABTL0812, creating potential pilot programs and research collaborations.

Strategic Funding Milestones With multiple financing rounds totaling over 21 million euros, Ability Pharma has secured substantial funding to accelerate drug development and clinical trials. Investors and strategic partners may find opportunities to co-invest or participate in future funding rounds, leveraging the company's proven fundraising ability and growth trajectory.

Regulatory Milestones The granting of Orphan Drug Designations by both the US FDA and European EMA for key indications provides a competitive edge, streamlining regulatory pathways, and enhancing market potential. This regulatory support is an attractive prospect for distribution, commercialization, and partnership opportunities in rare and underserved cancer markets.

Collaborative Expansion Partnerships with global institutions and pharma companies, such as AGC Pharma Chemicals and SciClone Pharmaceuticals, highlight opportunities for regional and international collaborations. Business development efforts can target expanding licensing, manufacturing, and distribution agreements to capitalize on the company’s innovative therapies in new markets and therapeutic areas.

Ability Pharmaceuticals, SL Tech Stack

Ability Pharmaceuticals, SL uses 8 technology products and services including Google Workspace, FancyBox, jQuery, and more. Explore Ability Pharmaceuticals, SL's tech stack below.

  • Google Workspace
    Email
  • FancyBox
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Google Maps
    Maps
  • YouTube
    Video Players
  • Google Analytics
    Web Analytics
  • Apache
    Web Servers
  • Apache HTTP Server
    Web Servers

Media & News

Ability Pharmaceuticals, SL's Email Address Formats

Ability Pharmaceuticals, SL uses at least 1 format(s):
Ability Pharmaceuticals, SL Email FormatsExamplePercentage
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
33%
First.Middle@abilitypharma.comJohn.Michael@abilitypharma.com
32%
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
2%
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
33%

Frequently Asked Questions

What is Ability Pharmaceuticals, SL's phone number?

Minus sign iconPlus sign icon
You can contact Ability Pharmaceuticals, SL's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ability Pharmaceuticals, SL's official website and social media links?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL's official website is abilitypharma.com and has social profiles on LinkedInCrunchbase.

What is Ability Pharmaceuticals, SL's SIC code NAICS code?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ability Pharmaceuticals, SL have currently?

Minus sign iconPlus sign icon
As of December 2025, Ability Pharmaceuticals, SL has approximately 23 employees across 2 continents, including EuropeNorth America. Key team members include Chief Business Officer: D. S.Chief Operating Officer: H. P. M.Vp Clinical & Regulatory Affairs: G. F. D.. Explore Ability Pharmaceuticals, SL's employee directory with LeadIQ.

What industry does Ability Pharmaceuticals, SL belong to?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL operates in the Biotechnology Research industry.

What technology does Ability Pharmaceuticals, SL use?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL's tech stack includes Google WorkspaceFancyBoxjQueryGoogle MapsYouTubeGoogle AnalyticsApacheApache HTTP Server.

What is Ability Pharmaceuticals, SL's email format?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL's email format typically follows the pattern of First.Last@abilitypharma.com. Find more Ability Pharmaceuticals, SL email formats with LeadIQ.

When was Ability Pharmaceuticals, SL founded?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SL was founded in 2009.

Ability Pharmaceuticals, SL

Biotechnology ResearchCatalonia, Spain11-50 Employees

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. 

AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel.

ABTL0812  has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard).

ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic.

The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. 

ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. 

Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Ability Pharmaceuticals, SL's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Ability Pharmaceuticals, SL's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.